+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease



Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease



Atherosclerosis 150(2): 413-419



A specific and robust immunoassay for the lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), platelet-activating factor acetylhydrolase, is described for the first time. The immunoassay was used to evaluate possible links between plasma Lp-PLA(2) levels and atherosclerosis risk amongst susceptible individuals. Such an investigation was important because Lp-PLA(2) participates in the oxidative modification of low density lipoprotein by cleaving oxidised phosphatidylcholines, generating lysophosphatidylcholine and oxidised free fatty acids. The majority of Lp-PLA(2) was found associated with LDL (approximately 80%) and, as expected, enzyme levels were significantly positively correlated to LDL cholesterol. Plasma Lp-PLA(2) levels were significantly elevated in patients with angiographically proven coronary artery disease (CAD) when compared with age-matched controls, even though LDL cholesterol levels did not differ significantly. Indeed, when included in a general linear model with LDL cholesterol and other risk factors, Lp-PLA(2) appeared to be an independent predictor of disease status. We propose, therefore, that plasma Lp-PLA(2) mass should be viewed as a potential novel risk factor for CAD that provides information related to but additional to traditional lipoprotein measurements.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010927338

Download citation: RISBibTeXText

PMID: 10856534

DOI: 10.1016/s0021-9150(99)00406-2


Related references

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism: Clinical and Experimental 47(2): 177-181, 1998

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Current Opinion in Lipidology 14(4): 347-352, 2003

Identification of the G994fwdarwT missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Circulation 96(8 Suppl. ): I230, 10/21/97, 1997

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis. Supplements 3(4): 57-68, 2002

Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis Suppl.s 3(4): 57-68, 2002

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovascular Drugs and Therapy 23(1): 73-83, 2009

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111(8): 980-987, 2005

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal 338: 479-487, 1999

Inhibitory effects of natural plant extracts on lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase. Korean Journal of Pharmacognosy 34(1): 100-108, 2003

Excretion of platelet activating factor-acetylhydrolase and phospholipase A-2 into nasal fluids after allergenic challenge: Possible role in the regulation of platelet activating factor release. Journal of Allergy and Clinical Immunology 94(1): 109-119, 1994

Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study. Inflammation 35(4): 1419-1428, 2012

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology 1(2): 121-125, 2001

Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase. Circulation Research 108(4): 469-477, 2011

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arteriosclerosis Thrombosis and Vascular Biology 19(12): 2909-2917, 1999

Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. Journal of Research in Medical Sciences 16(5): 674-679, 2011